193 completed, 26 terminated, 25 recruiting, 20 unknown. 297 Phase 1, 72 Phase 2.
Follow Dermatitis: new trials by email Literature Review of Dermatitis trials Research Report on Dermatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Multiple Ascending Doses (MAD) of M5542 in Participants With Moderate and Severe Eczema M5542 - Eczema | Phase 1 | Not yet recruiting | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 56 | 2026-12-20 | 2026-11-12 |
| Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis baricitinib - Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2026-11-18 | 2026-11-13 |
| A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants GLR2053 Tablets, Placebo - Atopic Dermatitis | Phase 1 | Not yet recruiting | Gan & Lee Pharmaceuticals. | 124 | 2026-11-05 | 2026-11-06 |
| A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis HSK60002 tablets, HSK60002 Placebo - Dermatitis Atopic | Phase 1 | Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | 60 | 2026-11-01 | 2026-11-06 |
| A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis NOR-101, Placebo - Atopic Dermatitis (AD) | Phase 1 | Not yet recruiting | North Immunology Inc. | 96 | 2026-11-01 | 2026-10-29 |
| Subconjunctival Humira for Boston Keratoprosthesis Adalimumab Injection - Penetrating Keratoplasty, Multiple Graft Failure | Phase 1 | Not yet recruiting | Massachusetts Eye and Ear Infirmary | 8 | 2026-10-01 | 2026-08-31 |
| Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis QX4533, QX4533 Placebo - Atopic Dermatitis | Phase 1 | Recruiting | QuantX Biosciences, Inc. | 84 | 2026-09-14 | 2026-10-02 |
| Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis HXN6005, Placebo - Health Adult Subjects, Atopic Dermatitis (AD) | Phase 1 / Phase 2 | Not yet recruiting | Helixon Biotechnology (Suzhou) Co., Ltd | 67 | 2026-09-01 | 2026-08-24 |
| A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis BYN-001, Placebo - Atopic Dermatitis, Healthy Participants | Phase 1 | Recruiting | Bionyra Pharma | 56 | 2026-08-17 | 2026-09-30 |
| A Clinical Study of HRS-8797 in Healthy Participants HRS-8797, Placebo - Atopic Dermatitis | Phase 1 | Not yet recruiting | Chengdu Suncadia Medicine Co., Ltd. | 74 | 2026-07-01 | 2026-07-13 |
| A Study to Evaluate the Multiple Dose Ascending of PG-033 in Healthy Adult Participants. PG-033 tablets, PG-033 placebo comparator - Lichen Simplex Chronicus | Phase 1 | Not yet recruiting | Prime Gene Therapeutics Co., Ltd. | 30 | 2026-06-04 | 2026-06-01 |
| A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis DCY636, Placebo - Dermatitis, Atopic | Phase 1 | Recruiting | Novartis Pharmaceuticals | 63 | 2026-06-02 | 2026-11-10 |
| Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease S-4321 - Autoimmune Diseases, Rheumatoid Arthritis (RA) | Phase 1 | Recruiting | Seismic Therapeutic AU Pty Ltd | 24 | 2026-06-01 | 2026-06-01 |
| A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants HXN5003, Placebo - Atopic Dermatitis | Phase 1 | Not yet recruiting | Helixon Biotechnology (Suzhou) Co., Ltd | 28 | 2026-05-27 | 2026-04-24 |
| HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis HL-300, Placebo - Atopic Dermatitis | Phase 1 / Phase 2 | Recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 156 | 2026-05-26 | 2026-06-23 |
| First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis REGN20423, Placebo - Healthy Volunteer, Atopic Dermatitis | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 160 | 2026-05-22 | 2026-11-06 |
| A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis IBI3033, Placebo - Atopic Dermatitis | Phase 1 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 16 | 2026-04-30 | 2026-04-24 |
| ZYG24002 Lotion to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Adult Patients With Mild to Moderate Seborrheic Dermatitis ZYG24002 0.5%, ZYG24002 0.75%, ZYG24002 1% - Seborrheic Dermatitis | Phase 1 | Recruiting | Sinomune Pharmaceutical Co., Ltd | 48 | 2026-04-24 | 2026-06-17 |
| A Food Effect Study of VC005 Tablets in Healthy Adult Subjects. VC005 Tablets - Atopic Dermatitis | Phase 1 | Completed | Jiangsu vcare pharmaceutical technology co., LTD | 31 | 2026-04-23 | 2026-06-08 |
| A Phase 1 Study of Cizutamig in IgE Mediated Diseases Cizutamig - IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy | Phase 1 | Withdrawn | Candid Therapeutics | 2026-04-01 | 2026-07-22 |
Showing 20 of 297. Sign in to see all of them.
Dermatitis, Atopic (227) · Eczema (34) · Radiodermatitis (13) · Psoriasis (10) · Asthma (9) · Stevens-Johnson Syndrome (9) · Pruritus (8) · Dermatitis, Contact (7) · Dermatitis, Phototoxic (6) · Skin Diseases (6) · Arthritis, Rheumatoid (4) · Breast Neoplasms (4) · Dermatitis, Allergic Contact (4) · Neurodermatitis (4)
Skin and Connective Tissue Diseases (297) · Skin Diseases (291) · Skin Diseases, Eczematous (256) · Immune System Diseases (246) · Hypersensitivity (241) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (230) · Genetic Diseases, Inborn (230) · Hypersensitivity, Immediate (227) · Skin Diseases, Genetic (227) · Pathological Conditions, Signs and Symptoms (20) · Wounds and Injuries (14) · Hypersensitivity, Delayed (13) · Respiratory Tract Diseases (13) · Skin Diseases, Papulosquamous (13)
dupilumab (6) · Clobetasol (4) · Midazolam (4) · Ointments (4) · 2-(6-(2-(3,5-dichloro-4-pyridyl)acetyl)-2,3-dimethoxyphenoxy)-N-propylacetamide (3) · Caffeine (3) · Metoprolol (3) · Norepinephrine (3) · Omalizumab (3) · Omeprazole (3) · Radiation (3) · Warfarin (3) · abrocitinib (3) · Exercise (2) · GSK1070806 (2)
Pfizer (15) · LEO Pharma (14) · GlaxoSmithKline (10) · National Institute of Allergy and Infectious Diseases (NIAID) (10) · Novartis Pharmaceuticals (6) · Regeneron Pharmaceuticals (6) · Amgen (4) · Jiangsu vcare pharmaceutical technology co., LTD (4) · Eli Lilly and Company (3) · Evelo Biosciences, Inc. (3) · Hangzhou Highlightll Pharmaceutical Co., Ltd (3) · Incyte Corporation (3) · ProCertus BioPharm, Inc (3) · Stiefel, a GSK Company (3) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (3)
United States (122) · China (51) · Germany (25) · Australia (20) · Canada (19) · United Kingdom (17) · Japan (14) · New Zealand (8) · Belgium (7) · South Korea (7) · Netherlands (6) · France (5) · Poland (5) · Spain (5) · Taiwan (4)
Richard Gallo, M.D., Ph.D. (3) · David Berk, MD (2) · Duncan McHale, MD, PhD (2) · Emanual Maverakis, MD (2) · Henry Milgrom, M.D. (2) · James Chodosh, MD, MPH (2)
PMID 25006719, PMID 25482871, PMID 36184023, PMID 17346444, PMID 18645136, PMID 22042247, PMID 23607128, PMID 23816920, PMID 24331381, PMID 25047038, PMID 25149431, PMID 25670894, PMID 26297574, PMID 26581111, PMID 26813208, PMID 26843086, PMID 27357167, PMID 27449926, PMID 28029926, PMID 28476287, PMID 28596000, PMID 29077711, PMID 29273054, PMID 29389078, PMID 29498038, PMID 29567358, PMID 30181143, PMID 30418579, PMID 31381020, PMID 31604104, PMID 32091548, PMID 32415720, PMID 32428543, PMID 32616515, PMID 33289844, PMID 33619370, PMID 33653805, PMID 33658996, PMID 34927195, PMID 35061234, PMID 35105560, PMID 35226304, PMID 35344588, PMID 35368221, PMID 35567671, PMID 36344555, PMID 36586583, PMID 37215725, PMID 37380711, PMID 37668898
2018 (6), 2014 (4), 2025 (2), 2008 (1), 2017 (1), 2023 (1)